contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lifecare-sanofi-product-development-agreement-update-2

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lifecare is a Norwegian company operating in medical technology. The company specializes in research and development of solutions for diabetes. The microsensors are injected under the skin of the patient's wrist, and also function as a real-time update of the patient's glucose level. In addition, the technology provides an alarm sensor and access to historical data on the patient's glucose level. The company was established in 2006 and is headquartered in Bergen, Norway.

Lifecare

Bergen, Norway, 29 October 2024: Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces the finalization of a...

<div class="mfn-preamble"><p><strong>Bergen, Norway, 29 October 2024: Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces the finalization of a new development phase under the Company’s Product Development Agreement with Sanofi.</strong></p></div><div class="mfn-body"><p>Reference is made to previous investor communication, dated 23 September 2021 and subsequent updates. Lifecare is engaged in a Product Development Agreement to advance the miniaturization of Lifecare’s sensor technology for integration into Lifecare’s Sencell Continuous Glucose Monitoring system.</p><p>Under the terms of the agreement, Sanofi has committed to providing financial contributions to support further development of Lifecare’s technology. In return, Lifecare has granted Sanofi a right of first refusal to negotiate a global and exclusive license (for human application) to Lifecares patented and proprietary glucose monitoring technology.</p><p>Upon completion of a defined development phase, Lifecare will today submit a phase-end report to Sanofi. This event triggers the release of funding contribution, while the Product Development Agreement continues in accordance with the development progress. This phase-end report does not directly activate commercial rights, but it highlights Lifecare’s commercial progress, demonstrating the achievement of previously reported technological milestones.</p><p>Subject to the continued development progress, Lifecare expects to submit the next phase-end report under the Product Development Agreement after completing its longevity study in dogs, targeted for Q1 2025. This report could potentially activate commercial rights, however, Lifecare has no indication at this stage as to whether these commercial rights will be triggered.</p></div><div class="mfn-footer mfn-6f66f307be9c"><p><strong class="mfn-heading-1">About us</strong><br>Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("<strong>CGM</strong>") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("<strong>NTR</strong>") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.</p></div><div class="mfn-footer mfn-contacts mfn-742f7fc5e6f2"><p><strong class="mfn-heading-1">Contacts</strong><br>For further information, please contact:<br><br>Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40</p><p>Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42<br><br></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/0ffac844-e8f2-486a-9817-06323d0a2177/lifecare-sanofi-product-development-agreement-update.pdf" class="mfn-generated mfn-primary">Lifecare - Sanofi Product Development Agreement Update</a></p></div>